



Omid Omidvar, M.D.
Apex Innovative Sciences
Collaborative Neuroscience Research, LLC.
Collaborative Neuroscience Network, LLC.
2600 Redondo Avenue, Suites 415 & 500
Long Beach, CA 90806

CONTACT INFORMATION:

Site Selection and Information:
Bobbie Theodore, Alliance Director
Tel. (916) 939-6696
Fax (208) 575-3169
Email: inquiries@apexsci.com

AFFILIATIONS:

Collaborative Neuroscience Research, LLC
Collaborative Neuroscience Network, LLC
12772 Valley View Street, Suite 3
Garden Grove, CA 92845

Collaborative Neuroscience Research, LLC
Collaborative Neuroscience Network, LLC
19401 S. Vermont Avenue, Suite F-100
Torrance, CA 90502

Ocean View Psychiatric Health Facility
2600 Redondo Avenue, Suites 415 & 500
Long Beach, CA 90806

Southland Neurologic Associates, Inc.
3851 Katella Ave. Ste 215
Los Alamitos, CA, 90720

Southland Neurologic Associates, Inc.
3747 Worsham Ave. Ste 100
Long Beach, CA, 90808

Los Alamitos Medical Center
3751 Katella Ave
Los Alamitos, CA 90720

Long Beach Memorial Medical Center
2801 Atlantic Avenue
Long Beach, CA 90806

CERTIFICATION:

Certified by the American Board of Psychiatry and Neurology in Neurology, March 2010

LICENSURE:

Licensed Physician and Surgeon, State of California, License No. A55552

EDUCATION:

June 1994 Diplôme d'Etat de Docteur en Médecine, France

INTERNSHIPS AND RESIDENCIES:

1996-98 Chief Resident in Neurology
Harbor-UCLA Medical Center, Torrance, CA

1995-98 Resident in Neurology
Harbor-UCLA Medical Center, Torrance, CA

1994-95 Internship in Internal Medicine
University of Nevada, Las Vegas, NV

1992-93 Internship in Internal Medicine and Emergency Medicine
University and Hospital Center of Rouen, France

PROFESSIONAL EXPERIENCE:

Investigator, 2019 – Present
Apex Innovative Sciences

Investigator, 2007 – Present
Collaborative Neuroscience Research, LLC, Long Beach, CA
Collaborative Neuroscience Network, LLC, Long Beach, CA

Private Practitioner, 1998 - Present
Southland Neurologic Associates, Los Alamitos, CA

Assistant Clinical Professor of Neurology, 2003-2012
David Geffen UCLA school of Medicine, Los Angeles, CA

Clinical Faculty, 1999-2012
Harbor-UCLA Medical Center, Torrance, CA

Vice Chairman of Department of Medicine, 2008-2009
Los Alamitos Medical Center, Los Alamitos, CA

Chairman of Pharmacy and Therapeutic Committee, 2006-2007
Los Alamitos Medical Center, Los Alamitos, CA

INVESTIGATOR EXPERIENCE:

Phase I-IV: Acute Poliomyelitis • Age-Associated Memory Impairment (AAMI)
Alzheimer's Disease • Chronic Pain • Dementia • Diabetes (Type II) • Epilepsy
Friedreich's Ataxia • Healthy • Migraine • Mild Cognitive Impairment • Multiple Sclerosis
Neurogenic Orthostatic Hypotension • Neuropathic Pain • Osteoarthritis • Parkinson's Disease
Post-Herpetic Neuralgia • Post-Polio Syndrome • Post-Stroke • Primary Autonomic Failure
Restless Legs Syndrome (RLS) • Spasticity • Schizophrenia or Schizoaffective Disorder

ADDITIONAL TREATMENT EXPERIENCE:

Fibromyalgia • Insomnia

CLINICAL TRIAL EXPERIENCE:

Phase I Alzheimer's Disease

A Phase I, Clinical Study to Evaluate a Cognitive Platform to Support Development of Symptomatic Therapies in Participants at Risk for Alzheimer's Disease

A Phase I, Multiple-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of XXX in Participants with Alzheimer's Disease

A Single-Dose and Multiple-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of XXX in Healthy Subjects and Patients with Alzheimer's Disease

A Phase Ib Study of the Pharmacokinetics and Safety of XXX in Subjects with Mild Alzheimer's Disease who are Heterozygous or Homozygous for the $\epsilon 4$ Variant of the Apolipoprotein E Gene (APOE 4 Carriers)

A Phase Ib, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Safety, Tolerability, Pharmacokinetics, and Brain Metabolic Response, Using FDG PET, Following Administration of XXX Added to Standard of Care (Donepezil \pm Memantine) in Participants with Mild to Moderate Alzheimer's Disease

A Phase I, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Dose Escalation Study of XXX in Patients with Probable Alzheimer's Disease

A Randomized, Double-Blind, Placebo-Controlled, Phase Ib, Safety, Tolerability, and Pharmacokinetic Study of Multiple Ascending Doses of XXX in Patients with Mild Alzheimer's Disease

A Phase I XXX Assay development using blood specimens from clinically diagnosed Alzheimer's disease subjects and healthy, cognitively intact control subjects

A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single- and Multiple-Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of XXX in Subjects with Mild to Moderate Alzheimer's Disease

A Phase I Recovery of Naturally Occurring Human Tau Antibodies

A Phase Ib, Randomized, Double-Blinded, Placebo-Controlled, Multiple- Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of XXX in Subjects with Mild or Prodromal Alzheimer's Disease

CLINICAL TRIAL EXPERIENCE (*continued*):

A Phase I, Single-Dose and Multiple-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of XXX in Patients with Mild Cognitive Impairment due to Alzheimer's Disease or Mild to Moderate Alzheimer's Disease

A Phase Ib/II study to assess the Safety, Tolerability, and (CSF) Pharmacodynamic Effects of XXX in patients with mild cognitive impairment (MCI) due to Alzheimer's Disease (AD) and mild Alzheimer's Disease (AD)

A Phase I, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Effects of Multiple Doses of XXX on Cerebrospinal Fluid Biomarkers, Connectivity Magnetic Resonance Imaging, and Computerized Cognitive Tests in Subjects with Mild Alzheimer's Disease

A Phase I, Double-Blind, Randomized, Placebo-Controlled, Multiple, Escalating Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of XXX in Elderly Volunteers and in Subjects With Mild Alzheimer's Disease

A Phase I, Randomized, Double-blind, Placebo-controlled, Combined Single Ascending Dose and Multiple Ascending Dose Study to Assess Safety, Tolerability, Immunogenicity, Pharmacodynamic Response, and Pharmacokinetics of Intravenous Infusions of XXX in Subjects With Mild to Moderate Alzheimer's disease

Phase I Multiple Sclerosis

A Phase I, Multicenter, Randomized, 12-Week, Open-Label Study to Evaluate the Multiple-Dose Pharmacokinetics and Pharmacodynamics of XXX in Patients with Relapsing Multiple Sclerosis

A Phase I Double-Blind, Placebo-Controlled, Single Ascending Dose Intravenous Infusion Study of XXX in Subjects with Multiple Sclerosis Immediately Following a Relapse

A Phase I, Double-Blind, Placebo-Controlled, Single Ascending Intravenous Infusion Study of XXX in Patients with Multiple Sclerosis

A Phase I, Multi-center, Open-Label Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacodynamic Activity of Intravenous XXX in subjects with Multiple Sclerosis

Phase I Parkinson's Disease

A Phase I, Randomized, Double-blind, Placebo-controlled Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses of XXX in Subjects with Parkinson's Disease

A Phase I, 2-Part, Open-label, Adaptive, Single and/or Multiple Oral Dose, Safety, Tolerability, and Food Effect Trial of XXX in Subjects with Parkinson's Disease

CLINICAL TRIAL EXPERIENCE (*continued*):

A Phase I, Double-blind, Placebo-controlled, Multiple Dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of XXX in Patients with Parkinson's Disease

A Phase I Randomized multi-center, open-label, crossover pharmacokinetic study of XXX and an oral dose of XXX under fed conditions in patients with Parkinson's Disease

A Phase Ib, Multicenter, Randomized, Placebo-controlled, Double-blind Study to Determine the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of XXX in Subjects with Parkinson's Disease

A Phase I, Open-Label Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Repeated Doses of XXX, and Effect on Levodopa Pharmacokinetics, in Subjects with Parkinson's Disease

A Phase I, Double-Blind, Placebo-Controlled Study to Determine Safety, Tolerability, Pharmacokinetics of XXX at Multiple Ascending Dose in Subjects with Parkinson's Disease

A Phase I, Double-blind, Sponsor Open, Randomized, Placebo-controlled, Single Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of XXX Co-Administered with XXX in Subjects with Idiopathic Parkinson's Disease

A Phase Ib, 2-Period, Open Label, Multicenter, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of XXX In Subjects with Parkinson's Disease and Motor Fluctuations

A Phase I, Randomized, Double-blinded, Multiple Ascending Dose Study in Patients with Early-stage Parkinson's Disease to Evaluate the Pharmacokinetics and Safety of XXX Following Intramuscular Injections

A Phase I, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study of XXX Administered By Intravenous Infusion in Patients with Parkinson's Disease

A Phase I, randomized, double-blinded, multiple ascending dose study in patients with early-stage Parkinson's disease to evaluate the pharmacokinetics and safety of XXX following intramuscular injections

A Phase I, Open-Label, Single Group, Multiple-Dose, Study to Evaluate the Pharmacokinetics of XXX following 24-hr Application in Patients Diagnosed with Parkinson's Disease

A Phase I, Randomized, Double-Blind, Placebo-Controlled, Ascending Dose Study of Safety and Tolerability of XXX in Adult Patients with Parkinson's Disease Who Are Receiving XXX Advanced Parkinson's Disease

CLINICAL TRIAL EXPERIENCE (*continued*):

Phase I Other Indications

A Phase I Double-blind, Placebo-Controlled, Multiple Ascending Dose Study to Determine the Safety, Tolerability and Pharmacokinetics of XXX Oral Solution in Healthy Adults with an Open-Label Cohort of Patients with Huntington's Disease

A Phase I, Study to Facilitate Discussion Sessions Between Individual Patients and Sponsor's Staff to Understand the Experience of their Medical Condition and Elicit Feedback on Potential Product Designs AND Assist with Establishing a Patient Advisory Panel for Regular Feedback on Prototypes of Product Designs and Features on a Recurring Basis

A Phase I, Randomized, Double-blind, controlled study to assess the Safety, Tolerability, and Pharmacokinetics of XXX in Patients with Friedreich's Ataxia

A Randomized, Double Blind, Placebo Controlled Trial to Study Difference in Cognitive Learning Associated with Repeated Self-Administration of Remote Computer Tablet-Based Application Assessing Dual-Task Performance Based on Amyloid Status in Healthy Elderly Volunteers

A Phase Ib, Parallel Group, Double-Blind, Randomized, Placebo Controlled to Evaluate the Safety, Pharmacokinetics, and Efficacy of a Single Dose of XXX Administered Intravenously in Patients with Frequent Episodic Migraines

A Phase I, Open-Label, Randomized, Parallel Group, Crossover Study to Compare the Pharmacokinetics of XXX in Migraine Subjects During an Acute Migraine Attack and During a Non-Migraine Period

Phase II-IV Studies

Alzheimer's Disease

A Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter, Phase II Study to Evaluate the Efficacy and Safety of XXX in Patients with Prodromal-to-Mild or Moderate Alzheimer's Disease

A Multicenter, Open-Label, Long-Term Extension of Phase III Studies of XXX in Patients with Alzheimer's Disease

A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, and Safety Study of XXX in Patients with Early (Prodromal to Mild) Alzheimer's Disease

CLINICAL TRIAL EXPERIENCE (*continued*):

A Phase II Prospective, Randomized, Double-Blind, Dose-Comparison Concurrent Control Study to Assess the Safety and Tolerability of XXX Infusions in Subjects with Mild to Moderate Alzheimer's Disease

A Phase III, Open Label Extension Study for Continued Safety and Efficacy Evaluation of XXX in Patients with Mild Alzheimer's Disease

Two Independent Trials: Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter, Phase II Study to Evaluate the Efficacy and Safety of XXX in Patients with Prodromal-to-Mild or Moderate Alzheimer's Disease

A Phase II, Randomized, Double-Blind, Placebo Controlled, parallel group study to evaluate the efficacy and safety of XXX in participants at risk for the onset of clinical symptoms of AD

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of XXX in the Treatment of Agitation in Patients with Dementia

A Phase II/III, Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of XXX for the Treatment of Agitation in Subjects with Dementia of the Alzheimer's Type

A Phase III, 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of XXX in Early Alzheimer's Disease (The XXX Study)

A Phase III, Multicenter, Long-term, Extension Study of the Safety and Efficacy of XXX for the Treatment of Agitation in Patients with Dementia of the Alzheimer's Type

A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of XXX for the treatment of agitation in patients with dementia of the Alzheimer's type

A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of XXX in Patients with Prodromal-to-mild Alzheimer's Disease

A Phase IIa, Randomized, Parallel Group, Placebo Controlled Study of 50 mg and 100 mg of XXX and Placebo in Subjects with Mild to Moderate Alzheimer's Disease Currently Treated with XXX and XXX

A Phase III, Randomized, Double-Blind, Placebo Controlled, Multi-Center Registration Trial To Evaluate The Efficacy And Safety Of TTP488 In Patients With Mild Alzheimer's Disease Receiving XXX And/Or XXX

CLINICAL TRIAL EXPERIENCE (continued):

A Phase III, 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of 3 Fixed Doses of XXX in the Treatment of Subjects with Agitation Associated with Dementia of the Alzheimer's Type

A 2-month, Observational, Rollover Trial to Evaluate the Safety of Subjects with Agitation Associated with Dementia of the Alzheimer's Type who were Previously Treated with XXX or Placebo in a Phase III, Double-blind Trial

A Phase III, Effect of XXX, an anti-amyloid beta monoclonal antibody, on the progression of Alzheimer's disease as compared with placebo

A Phase III, Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneously Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI due to AD) and to Test the Safety and Efficacy of XXX to Delay the Onset of MCI due to AD in Cognitively Normal Subjects

An Open-Label, Extension Study of the Effects of XXX in Subjects with Alzheimer's Disease or Behavioral Variant Frontotemporal Dementia

A 26-Week Extension Study of the Safety and Clinical Effects of XXX in Subjects with Alzheimer's Disease Currently or Previously Receiving an Acetylcholinesterase Inhibitor Medication

A Randomized, Double-Blind, Placebo-Controlled, Parallel, 26-Week, Phase III Study of Two Doses of XXX, an Alpha-7 Nicotinic Acetylcholine Receptor Partial Agonist, or Placebo in Subjects with Mild to Moderate Probable Alzheimer's Disease with or without Acetylcholinesterase Inhibitor Medication

A Phase II/III randomized, placebo-controlled, parallel-group, double blind clinical trial to study the efficacy and safety of XXX in subjects with mild cognitive impairment due to Alzheimer's Disease (prodromal AD)

A Phase III Effect of XXX, an anti-amyloid beta monoclonal antibody, on the progression of Alzheimer's disease as compared with placebo

A Phase II, 12-Week Safety Extension Study of Oral XXX for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease

A Phase II six month, double-blind, randomized, placebo-controlled, parallel-group study to investigate the effects of daily administration of XXX in subjects with mild to moderate AD

A Prospective, Randomized, Double-Blind, Placebo-Controlled, Phase II Efficacy and Safety Study of XXX for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease

CLINICAL TRIAL EXPERIENCE (continued):

A Phase III Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 18-month Safety and Efficacy Study of XXX in Subjects with Mild Alzheimer's Disease

A Phase II Placebo-controlled, Double-blind, Parallel-group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study to Evaluate Safety, Tolerability and Efficacy of XXX in Subjects With Early Alzheimer's Disease

A Phase II, Long-Term Safety and Tolerability of XXX in Subjects with Mild-to-Moderate Alzheimer's Disease on Stable Doses of XXX: An Open-Label Extension Study for Subjects Completing Study XXX

A Phase II, Randomized, Placebo Controlled, Parallel-Group, Double Blind Efficacy and Safety Trial of XXX in Subjects with Mild to Moderate Alzheimer's Disease

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of XXX in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

A Phase III Randomized, Double-blind, Placebo-Controlled Study of the Safety and Effectiveness of XXX for the Treatment of Mild to Moderate Alzheimer's Disease (AD)

A Phase IIIb Study of Subjects With Alzheimer's Disease Who Discontinued Treatment in XXX Phase III Clinical Studies XXX or Who Completed Studies XXX but did not Enroll in Study XXX

A Phase IIb, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Biomarker, Safety, and Pharmacokinetic Study of XXX Administered Subcutaneously at Monthly Intervals in Subjects with Mild to Moderate Alzheimer Disease

A Phase III, Open Label Extension of XXX Evaluating XXX in Patients with Alzheimer's Disease

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Trial of XXX in Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E ϵ 4 Non-Carriers

A 2-Part, Randomized, Double Blind, Sequential, Multiple Ascending Dose, Placebo Controlled, Parallel Group Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of XXX in Elderly Subjects with and without Alzheimer's Disease

A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Safety and Efficacy Study of Oral XXX in Alzheimer's Disease

CLINICAL TRIAL EXPERIENCE (*continued*):

A 24 Week Open-Label Extension to Study XXX: A 24 Week, Prospective, Randomized, Parallel-Group, Double-Blind, Multi-center Study Comparing the Effects of XXX vs. XXX on Activities of Daily Living and Cognition in Patients with Severe Dementia of the Alzheimer's Type (ACTION)

A 24 Week, Prospective, Randomized, Parallel-Group, Double-Blind, Multi-center Study Comparing the Effects of XXX vs. XXX on Activities of Daily Living and Cognition in Patients with Severe Dementia of the Alzheimer's Type

A Multi-center, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, Pharmacodynamic and Pharmacokinetic Effects of XXX in the Treatment of Patients with Prodromal Alzheimer's Disease AND PET sub-study

A Phase III, Multicenter, Parallel-Group, Long Term Safety and Tolerability Treatment Trial of XXX in subjects with Alzheimer's Disease who Participated in Study XXX or in Study XXX

A Multi-center, Randomized Double-Blind Placebo-Controlled Study of the Safety, Tolerability, Pharmacodynamic and Pharmacokinetic Effects of XXX in the Treatment of Patients with Mild to Moderate Alzheimer's Disease

A Randomized Controlled Trial to Assess the Efficacy of a Medical Food in Patients with Mild to Moderate Alzheimer's Disease using Alzheimer's Disease Medication

A Phase III Multi-center, Randomized, Placebo-Controlled, Double-Blind, Twelve-Month Safety and Efficacy Study Evaluating XXX in Patients with Mild-to-Moderate Alzheimer's Disease on XXX

A Randomized, Open-Label, Three-Period Cross-Over Study in Healthy Subjects to Compare the Pharmacokinetic Profiles of a 7-Day Application of the XXX Transdermal Patch-System to Three Different Skin Sites

A Phase III, Multi-center, Parallel-Group, Long Term Safety and Tolerability Treatment Trial of XXX in Subjects with Alzheimer's Disease Who Participated in Study XXX or in Study XXX

A Phase III, Multi-center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Efficacy and Safety Trial of XXX in Patients with Mild to Moderate Alzheimer's Disease who are Apolipoprotein E 4 Non-Carriers AND A Phase III, Multi-center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Trial of XXX in Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E4 Carriers

A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Safety and Efficacy Study of Oral XXX in Alzheimer's Disease

CLINICAL TRIAL EXPERIENCE (*continued*):

Ataxia

A Randomized, Double-Blind, Controlled, Phase II/III Study to Assess Efficacy, Long Term Safety and Tolerability of XXX in Subjects with Friedreich's Ataxia

A Phase IIb/III, Randomized, Double-blind, Placebo-controlled Trial of XXX in Adult Subjects with Spinocerebellar Ataxia

A Phase IIb/III, Randomized, Double-blind, Placebo-controlled Trial of XXX in Adult Subjects with Spinocerebellar Ataxia

Diabetes

A Phase IIIb, 24-week, Randomised, Placebo-Controlled, Double-Blinded, Efficacy and Safety Study of XXX in Black/African American Patients with Type 2 Diabetes with a MTT Sub-Study

A Phase III 24-week, Multi-Centre, Randomized, Double-Blind, Age-Stratified, Placebo-Controlled Phase III Study with a 28-Week Extension Period to Evaluate the Efficacy and Safety of XXX 10 mg Once Daily in Patients with Type 2 Diabetes and Cardiovascular Disease, who Exhibit Inadequate Glycemic Control on Usual Care

Epilepsy

A Historical-controlled, Multicenter, Double-blind, Randomized Trial to Assess the Efficacy and Safety of Conversion to XXX Monotherapy in Subjects with Partial-onset Seizures

A Phase III, Multi-center, Open-Label Study Designed to Assess the Safety and Tolerability of Intravenously Administered XXX in Adult Subjects with Epilepsy. This Study will Include a 28 day Lead-in Period, a Confinement Period (up to 7 days and 6 nights) and a 28 day Follow-up Period

Efficacy and Safety of XXX as Adjunctive Therapy for Refractory Partial Seizures in a Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multi-centre Clinical Trial

A Randomized, Double-Blind, Parallel-Group, Multicenter Study to Evaluate the Retention Rate, Efficacy, Safety, and Tolerability of XXX, XXX, and XXX as Adjunctive Therapy in Subjects with Partial Onset Seizures

Conversion to Monotherapy for Adults with Epilepsy Experiencing Partial Seizures (with or without Secondary Generalization), A Historical-controlled, Multicenter, Double-blind, Randomized Trial to Assess the Efficacy and Safety of Conversion to XXX Monotherapy in Subjects with Partial-onset Seizures

CLINICAL TRIAL EXPERIENCE (*continued*):

An International, Double-Blind, Randomized, Multi-center, Parallel Group, Historical-Control Conversion to Monotherapy Study to Evaluate the Efficacy and Safety of XXX in Subjects (≥ 16 to 75 years old) with Partial Onset Seizures with or without Secondary Generalization

A Double-Blind, Randomized, Historical Control Study of the Safety and Efficacy of XXX Monotherapy in Subjects with Partial Epilepsy Not Well Controlled by Current Antiepileptic Drugs and Long-Term Extension XXX Study for the XXX Double-Blind Monotherapy Study

Hypotension

A Phase III, 24-week, Multi-center, Randomized Withdrawal Study of XXX in Treating Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure

A Phase III, 4-week, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of XXX in Treating Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure

A Phase II Study to Assess the Effect and Safety of XXX in Subjects with Neurogenic Orthostatic Hypotension

Migraine

A Phase II, Multicenter, Randomized, Proof-of-Concept, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 1 Subcutaneous Dose Regimen of XXX Versus Placebo for the Prevention of Persistent Posttraumatic Headache (PPTH)

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety and Tolerability of monthly Subcutaneous Administration of XXX Versus Placebo for the Preventive Treatment of Migraine in patients with inadequate response to 2 to 4 other preventive treatments

A Open Label Trial to Evaluate the Safety of XXX Administered Intravenously in Patients with Chronic Migraines

A Parallel Group, Double-Blind, Randomized, Placebo Controlled, Phase III Trial to Evaluate the Efficacy, and Safety, of XXX Administered Intravenously in Patients with Chronic Migraine

A Phase III, Multicenter, Randomized, Double-Blind, Parallel-Group Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Subcutaneous Administration of XXX for the Preventive Treatment of Migraine

A Phase III, Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 2 dose regimens of subcutaneous administration of XXX versus Placebo for the Preventive Treatment of Episodic Migraine

CLINICAL TRIAL EXPERIENCE (*continued*):

A Phase III, Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 2 dose regimens of subcutaneous administration of XXX versus Placebo for the Preventive Treatment of Chronic Migraine

A Phase II, Open Label Trial to Evaluate the Safety of XXX Administered Intravenously in Patients with Migraine

A Phase II, Parallel Group, Double-Blind, Randomized, Placebo Controlled, Trial to Evaluate the Efficacy and Safety of XXX Administered Intravenously in Patients with Migraines

A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of XXX in Patients with Episodic Migraine

A Multicenter, Double-Blind, Placebo-Controlled, Parallel Group, Multi-dose Study to Compare the Efficacy and Safety of Subcutaneous XXX with Placebo for the Preventive Treatment of Chronic Migraine

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous XXX with Placebo for the Preventive Treatment of High Frequency Episodic Migraine (HFEM)

A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of XXX in Patients with Migraine

A Six Month Phase II/III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety, Tolerability and Efficacy of XXX for Prevention of Menstrually Related Migraine in Female Patients with Episodic Migraine

A Study of the Chronic Intermittent Use of XXX, XXX, and XXX in the Acute Treatment of Migraine Attacks with or without Aura in Adults to Evaluate the Effect on Blood Pressure

A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Crossover Study to Evaluate the Efficacy of XXX Versus XXX Containing Combination Medications for the Acute Treatment of Migraine When Administered During the Moderate-Severe Pain Phase of the Migraine

A Randomized, Double Blind, Placebo Controlled, Parallel Group Study of XXX in Adult Migraineurs

Multiple Sclerosis

A Phase III, randomized, double-blind, efficacy and safety study comparing XXX to placebo in participants with primary progressive multiple sclerosis

CLINICAL TRIAL EXPERIENCE (*continued*):

A Phase III, Randomized, Double-blind, Efficacy and Safety Study Comparing XXX to Placebo in Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis

A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of XXX with an Active Control Group Interferon Beta 1a XXX, in Participants with Relapsing Multiple Sclerosis to Evaluate Efficacy and Safety.

A Phase II, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Ranging, Multi-Center Trial to Evaluate the Efficacy and Safety of XXX Injection for the Treatment of Upper Limb Spasticity in Adults After Stroke or Traumatic Brain Injury

A Phase III Multicenter, Open-Label Safety and Efficacy Study of XXX Extended Release Capsules in Patients with Multiple Sclerosis and Walking Impairment

A Phase III, 3-Arm, Multicenter, Double-Blind, Placebo-Controlled, Randomized Study to Assess the Efficacy and Safety of XXX Extended Release Capsules in Multiple Sclerosis Patients with Walking Impairment

A Phase III, Open-Label Study to Evaluate the Long-Term Safety of XXX Extended-Release Tablets in Multiple Sclerosis Patients with Spasticity

A Phase III, Randomized, Double-Blind, Placebo-Controlled Parallel Group Study to Investigate the Safety and Efficacy of XXX Extended-Release Tablets for the Treatment of Spasticity in Patients with Multiple Sclerosis

A Phase III XXX In Multiple Sclerosis Treatment Effects XXX Study. A 120 week, Phase III, randomized, multi-center, double-blinded, double-dummy, active-controlled study that is primarily designed to assess the ARR and safety/ tolerability of XXX as compared to XXX placebo in subjects with RMS

A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study in Subjects With Relapsing Multiple Sclerosis to Evaluate the Efficacy and Safety of XXX as an Add-On Therapy to Anti-Inflammatory Disease-Modifying Therapies

A Phase III Study in Subjects with Relapsing Remitting Multiple Sclerosis to Evaluate the Tolerability of XXX and XXX

A Phase III, Open Label Study to Evaluate the Long-term Safety and Tolerability of XXX in Subjects with Relapsing Remitting Multiple Sclerosis

A Phase III, Open-label study to Assess the Effects of XXX on lymphocyte subsets in subjects with relapsing-remitting multiple sclerosis

A Phase III, multi-site, open-label extension trial of oral XXX in relapsing multiple sclerosis

CLINICAL TRIAL EXPERIENCE (*continued*):

A Phase III, Multi-center, Randomized, Double-blind, Double-dummy, Active controlled, Parallel Group Study to Evaluate the Efficacy and Safety of XXX Administered Orally to Relapsing Multiple Sclerosis Patients

A Multicenter, treatment blind Phase IIIb study to evaluate whether 6 week up-titration in XXX dose is effective in reducing the Incidence of Gastro-Intestinal adverse events in relapsing-remitting Multiple Sclerosis patients

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy of XXX on Reducing Disability Progression in Subjects With Secondary Progressive Multiple Sclerosis (SPMS)

A Phase II/III, Multi-center, Randomized, Double-blind, Placebo-controlled (Part A) and Double-blind, Double-dummy, Active-controlled (Part B), Parallel Group Study to Evaluate the Efficacy and Safety of XXX Administered Orally to Relapsing Multiple Sclerosis Patients

A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of XXX Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients

A Double-Blind, Randomized, Placebo-Controlled, Parallel Group Trial to Evaluate the Duration of Action of XXX in Subjects with Spasticity due to Multiple Sclerosis

A Phase III, Randomized, Double-Blind, Parallel Group Study to Compare the Safety and Efficacy of Increasing Doses of XXX Extended Release Tablets to Placebo and XXX Tablets, for the Treatment of Spasticity in Patients with Multiple Sclerosis

A Phase II, randomized, partially blind, placebo-controlled, proof-of-concept study to assess the effect of a single infusion of XXX on disease activity as measured by brain MRI scans in patients with relapsing-remitting multiple sclerosis

A Phase III, Open-Label, Randomized, Multi-Center, Parallel-Arm Study to Assess the Safety and Tolerability of XXX 40 mg/mL Three Times a Week Compared to 20 mg/mL Daily Subcutaneous Injections in Subjects with Relapsing-Remitting Multiple Sclerosis

A Phase III, Open Label, 26-Week Study Assessing XXX Safety and Efficacy in Subjects with Spasticity Associated with Multiple Sclerosis with an Addendum Open-Label, 36-Week Study Assessing XXX Safety in Subjects with Spasticity Associated with Multiple Sclerosis

An Open Label, 26-Week Study Assessing XXX Safety and Efficacy in Subjects with Spasticity Associated with Multiple Sclerosis

A Randomized, Double Blind, Placebo-Controlled Efficacy and Safety Study of XXX in Subjects with Spasticity due to Multiple Sclerosis

CLINICAL TRIAL EXPERIENCE (*continued*):

A Multicenter, Observational, Open-Label, Single-Arm Study of XXX in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

A Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Two Doses of Oral XXX Extended Release Tablets (5 mg and 10 mg twice daily) in Patients with Multiple Sclerosis

JCV Antibody Program in Patients with Relapsing Multiple Sclerosis Receiving or Considering Treatment with XXX

MS (multiple sclerosis) Trak Study: 1999

A Phase III Randomized, Double-Blind, Double Dummy, Parallel-Group Study To Evaluate the Efficacy and Safety Of XXX In Comparison To XXX In Patients With Relapsing Multiple Sclerosis AND Extension Study

Pain

A Phase II, Randomized, Double-blind, Placebo-controlled, Dose-range finding Study to Assess the Efficacy and Safety of Intramuscular Injections of Human Placenta-derived Cells (XXX) in Subjects with Diabetic Peripheral Neuropathy

A Phase III, double-blind, randomized, placebo-controlled, multicenter study evaluating the efficacy and safety of XXX in subjects with Painful Diabetic Peripheral Neuropathy

A Randomized, Double-Blind, Placebo and Active Comparator-Controlled Study of XXX for Treatment of Neuropathic Pain Associated with Diabetic Peripheral Neuropathy

A Randomized, Placebo-Controlled Trial of XXX Added to Nonsteroidal Anti-inflammatory Drugs in Patients with Knee Pain due to Osteoarthritis who have had Suboptimal Response to Nonsteroidal Anti-inflammatory Drug Treatment

A Phase II, Multicenter, Randomized, Double-Blind, Placebo, Active Controlled Study Comparing the Analgesic Efficacy and Safety of XXX to Placebo in Subjects with Diabetic Neuropathic Pain

A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy, Safety and Tolerability of XXX in Subjects with Diabetic Painful Neuropathy and Small Fiber Neuropathy Associated with Impaired Glucose Tolerance Followed by a Double-Blind Safety Extension and an Open Label Safety Extension

An Open-label, Multi-center Trial to Assess the Long-term Safety and Efficacy of XXX in Opioid-experienced Subjects with Chronic Noncancer Pain

CLINICAL TRIAL EXPERIENCE (*continued*):

A Phase II Randomized, Double Blind Multi-Dose, Active- and Placebo-Controlled, Multi-Center, Parallel Group Study of the Analgesic Effect of XXX in Adult Patients with Chronic Low Back Pain

A Phase III Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Analgesic Efficacy and Safety of the Subcutaneous Administration of XXX in Patients with Osteoarthritis of the Knee

A Randomized, Multi-center, Double-Blind, Parallel-Group Trial with Controlled Adjustment of Dose Assessing the Analgesic Efficacy and Safety of a New Analgesic Compared with Placebo in Subjects with Painful Diabetic Peripheral Neuropathy

A Phase IIb Repeat Dosing Clinical Trial of XXX in Subjects with Moderately Severe Diabetic Neuropathy

A Randomized, Double-Blind, Placebo-Controlled, Phase IIa Proof-of-Concept Study To Evaluate The Efficacy Of Maximally Tolerated Doses of XXX vs. Placebo In Reducing The Pain Associated With Post-Herpetic Neuralgia

A Multi-center, Randomized, Double-Blind, Placebo-Controlled, Parallel Study Comparing the Analgesic Efficacy and the Safety of XXX (1 Mg, 2 Mg, And 4 Mg), XXX (60 Mg) and Placebo in Approximately 275 Subjects with Diabetic Neuropathic Pain

Parkinson's Disease

A Phase III, 58-Week Open-Label Trial of XXX in Parkinson's Disease

A Randomized, Double-blind, Placebo-controlled Phase IIb Study Evaluating the Efficacy of XXX on Daily ON-time Without Troublesome Dyskinesia in Patients With Parkinson's Disease

A Randomized, Double-Blind, Placebo-Controlled, 2-Period Crossover, Phase II Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral XXX in Parkinson's Patients with Cognitive Impairment and an Elevated Risk of Falls

A Phase II, Open-Label Evaluation of the Safety and Tolerability of XXX in Participants with Parkinson's Disease Mild Cognitive Impairment

A Phase III, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Flexible-Dose, 27-Week Trial to Evaluate the Efficacy, Safety, and Tolerability of XXX as Adjunctive Therapy for Parkinson's Disease in Levodopa-Treated Adults With Motor Fluctuations

A Phase II, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of XXX in Parkinson's Disease Patients with Motor Fluctuations

CLINICAL TRIAL EXPERIENCE (*continued*):

A Phase III, Multicenter, Randomized, Active-controlled, Double-blind, Double Dummy, Parallel Group Clinical Trial, Investigating the Efficacy, Safety, and Tolerability of Continuous Subcutaneous XXX Infusion in Comparison to Oral IR-LD/CD in Subjects with Parkinson's Disease Experiencing Motor Fluctuations

A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Fixed-dosage, Phase IIa Study Comparing 3 Dosages of XXX (10, or 30, or 75 mg administered orally [or 50 mg based on interim analysis] once a day [QD]) with Placebo over 12 weeks in Subjects with Mild-to-Moderate PDD.) Effect of XXX on Cognition in Mild to Moderate Parkinson's Disease Dementia (PDD) (The XXX Study)

A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Pharmacokinetics, and Pharmacodynamics of XXX in Subjects with Parkinson's Disease

A Phase IIa, Double-Blind, Placebo-Controlled, Two-Part study to investigate the safety and efficacy of increasing doses of XXX in Parkinson's Disease (PD) Subjects with motor fluctuations

A Phase III, Multicenter, Open-Label Study to Evaluate the Safety and Tolerability of XXX in Patients with Parkinson's Disease

A Phase II, Study to Assess the PK and Pharmacodynamics (PD) of XXX in Patients With Advanced Parkinson's Disease

A Phase III, Randomized, Double-blind, Placebo-Controlled Study Investigating the Efficacy and Safety of XXX in Parkinson's Disease Patients With Motor Response Fluctuations (OFF Phenomena)

A Phase III, 12-Month, Dose-Level Blinded Study Investigating the Safety and Efficacy of XXX in Parkinson's Disease Patients With Motor Response Fluctuations (OFF Phenomena)

A Phase IV, 24-Week, Multicenter, Randomized, Double-blind, Placebo-Controlled, Add-on, Parallel-Group Study to Assess the Effect of XXX on Cognition in Patients with Parkinson's Disease

A Phase IIa, Multi Centre, Double-Blind, Randomized, Placebo-controlled, Parallel-group Safety and Tolerability Study to Assess the Safety and Tolerability of oral XXX in Patients with Parkinson's Disease

An Extended Release XXX Safety and Efficacy Study in Levodopa-Induced Dyskinesia

A Phase II, Randomized, Open-Label, Crossover Study to Compare XXX to an Immediate-Release Carbidopa/Levodopa Tablet in Patients with Advanced Parkinson's Disease with Motor Fluctuations

CLINICAL TRIAL EXPERIENCE (*continued*):

A Phase III, 40-Week, Active-Controlled, Double-Blind, Double-Dummy Extension Study of XXX in Subjects With Moderate to Severe Parkinson's Disease

A Phase III, 12-Week, Double-Blind, Placebo-Controlled Efficacy and Safety Study of XXX in Subjects with Moderate to Severe Parkinson's Disease

A Phase II Efficacy, Safety and Pharmacokinetic Study of XXX and XXX in Parkinson's Disease Subjects with Motor Fluctuations

A Phase IIa, Randomized, Double-Blind, Cross Over Study Comparing the Tolerability of Two Dose Regimens of XXX in Adult Patients with Parkinson's Disease who are Receiving XXX

A Study to Evaluate the Safety and Efficacy of XXX in Advanced Parkinson's Disease

A Placebo-controlled Study to Evaluate the Safety and Efficacy of XXX in Subjects with Parkinson's Disease

An Open Label Extension Study of the Safety and Clinical Utility of XXX in Subjects with Parkinson's Disease (the "Study"), bearing protocol number XXX

A Randomized, Double-Blind, 2-Way Crossover Study to Compare XXX to Standard Carbidopa-Levodopa and Characterization of Multiple-Dose Pharmacokinetics and Pharmacodynamics of XXX in Levodopa-Experienced Parkinson's Disease Subjects with Motor Complications

A Multi-center, Double Blind, Parallel-Group Placebo and XXX Controlled Study to Explore the Efficacy, Tolerability and Safety of Different Doses and Titration Schedules of XXX Monotherapy in the Treatment of Patients with Early Stage Parkinson's Disease

A Study to Compare Pharmacokinetics and Pharmacodynamics of XXX to XXX

Other Indications

A Phase II, Double-blind, Placebo-controlled, Randomized Study Evaluating the Efficacy, Safety, and Tolerability of XXX in the Treatment of Individuals with Essential Tremor

A Phase II/III, Multicenter, Prospective, Randomized, Placebo-controlled, Double-blind, Parallel-group Clinical Trial to Assess the Efficacy and Safety of Immune Globulin Intravenous (Human) XXX in Patients with Post-Polio Syndrome

A Phase II, Randomized, Double-Blind, 6-Sequence, Placebo-Controlled, 2-Period Multicenter Crossover Study to Evaluate the Safety and Efficacy of XXX in Subjects with Spasticity due to Spinal Cord Injury

CLINICAL TRIAL EXPERIENCE (continued):

A Phase II, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing XXX with Placebo in Subjects with Age-Associated Memory Impairment (AAMI)

A Prospective, double-blind, placebo-controlled, randomized, multi-center study with an open-label extension period to investigate the efficacy and safety of XXX in the treatment of post-stroke spasticity of the lower limb

A Randomized, Double-Blind, Placebo Controlled Trial of Neuroprotective XXX Therapy for Acute Stroke Initiated Within 2 Hours of Onset by Paramedics in the Field

A Multi-center, Open-Label Study to Assess the Long-Term Safety of XXX in Subjects with Primary Autonomic Failure, Dopamine Beta Hydroxylase Deficiency or Non-Diabetic Neuropathy and Symptomatic Neurogenic Orthostatic Hypotension

A Fixed Dose Randomized, Double-Blind, 12-week Study of XXX Subjects with Moderate to Severe Idiopathic Restless Legs Syndrome

A Multi-center, Double-Blind, Randomized, Placebo-Group Induction Design Study to Assess the Clinical Effect of XXX in Subjects with Primary Autonomic Failure, Dopamine Beta Hydroxylase Deficiency

A Fixed-dose, Randomized, 12-Week Placebo-Controlled, 52-week Comparator-Controlled, Double-Blind Study to Assess the Rates of Augmentation, Efficacy and Safety of XXX and XXX in Subjects with Moderate to Severe Idiopathic RLS

AWARDS:

Outstanding Teaching Attending, 1998-1999, St. Mary's Medical Center
Affiliated with UCLA School of Medicine Top Doctor's – Consumer's Checkbook 2002 and 2009
Resident Scholarship Award Recipient 1997

MEMBERSHIPS:

American Academy of Neurology 1996 - Present
California Medical Association

THESIS:

Presented at the Faculté de Médecine de Rouen on June 17, 1994. This thesis was awarded among the highest qualifications of French rankings: **Félicitation des jurées, Mention très Honorables, Echange Internationale: Régions cérébrales participant à la réponse ventilatoire lors de l'application des charges resistives chez l'homme, études par L'IRM.**

RESEARCH PROJECTS:

Study of Respiratory Centers and Functional MRI, under Professor R.M. Harper and Dr D. Gozal, Department of Neuroanatomy, Brain Research Institute, UCLA School of Medicine

ABSTRACTS AND PUBLICATIONS:

T. Vollmer, O. Omidvar, An Ongoing Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Arbaclofen Placarbil in Subjects with Spasticity Due to Multiple Sclerosis, Abstract Number 660, presented at the American Academy of Neurology 65th Annual Meeting, March 2013, San Diego Convention Center, San Diego, CA

D. Gozal, O. Omidvar, K.A.T. Kirlew, G. M. Hathout, R. M. Hamilton, J. Zhang, R.B. Lufkin and R.M. Harper, Identification of human brain regions underlying responses to inspiratory loading with functional magnetic resonance imaging, *Proceedings of National Academy of Sciences USA*, Vol. 92 pp. 6607-6611, July 1995.

D. Gozal, O. Omidvar, K.A.T. Kirlew, G. M. Hathout, R. M. Hamilton, J. Zhang, R.B. Lufkin and R.M. Harper, Functional magnetic resonance imaging reveals brain regions mediating the response to resistive expiratory loads in humans, *Journal of Clinical Investigation*, Vol. 97 no. 1 pp. 47-53, Jan. 1996.

G. Aljadeff, D. Gozal, J. L. Carroll D. Rector, O. Omidvar, R. K. Harper, R.M. Harper, Ventral medullary surface responses to transient hypoxia and hyperoxia in the cat: Effect of carotid sinus denervation, Brain Research Institute; UCLA School of Medicine. Abstract presented at the 1994 annual meeting of the Society for Neuroscience.

LANGUAGES:

English, French, Farsi and some Spanish.